2/28
07:02 pm
rlay
Relay Therapeutics (RLAY) Valuation After Breakthrough Therapy Win And Narrower Loss Attracts Fresh Investor Interest [Yahoo! Finance]
Medium
Report
Relay Therapeutics (RLAY) Valuation After Breakthrough Therapy Win And Narrower Loss Attracts Fresh Investor Interest [Yahoo! Finance]
2/27
01:11 pm
rlay
Relay Therapeutics (RLAY) had its price target raised by Wells Fargo & Company from $13.00 to $15.00. They now have an "overweight" rating on the stock.
Medium
Report
Relay Therapeutics (RLAY) had its price target raised by Wells Fargo & Company from $13.00 to $15.00. They now have an "overweight" rating on the stock.
2/26
04:22 pm
rlay
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones [Yahoo! Finance]
High
Report
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones [Yahoo! Finance]
2/26
04:05 pm
rlay
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
High
Report
Relay Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Outlines Anticipated 2026 Milestones
2/23
04:37 pm
rlay
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March [Yahoo! Finance]
Low
Report
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March [Yahoo! Finance]
2/23
04:05 pm
rlay
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
Low
Report
Relay Therapeutics to Participate in Two Upcoming Investor Conferences in March
2/19
06:30 pm
rlay
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 [Yahoo! Finance]
Low
Report
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026 [Yahoo! Finance]
2/19
05:55 pm
rlay
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
Low
Report
Relay Therapeutics to Announce Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights on February 26, 2026
2/7
04:11 pm
rlay
Assessing Relay Therapeutics (RLAY) Valuation After FDA Breakthrough Therapy Designation For Zovegalisib [Yahoo! Finance]
Low
Report
Assessing Relay Therapeutics (RLAY) Valuation After FDA Breakthrough Therapy Designation For Zovegalisib [Yahoo! Finance]
2/4
04:05 pm
rlay
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Medium
Report
Relay Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
2/3
07:52 am
rlay
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer [Yahoo! Finance]
Low
Report
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer [Yahoo! Finance]
2/3
07:00 am
rlay
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
Low
Report
Relay Therapeutics Announces Zovegalisib Granted Breakthrough Therapy Designation by U.S. FDA for PIK3CA-mutant, HR+/HER2- Advanced Breast Cancer
1/26
07:19 am
rlay
Relay Therapeutics (NASDAQ:RLAY) was upgraded by analysts at Oppenheimer Holdings, Inc. from a "market perform" rating to an "outperform" rating.
Medium
Report
Relay Therapeutics (NASDAQ:RLAY) was upgraded by analysts at Oppenheimer Holdings, Inc. from a "market perform" rating to an "outperform" rating.
1/13
04:06 am
rlay
Relay Therapeutics (NASDAQ:RLAY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Relay Therapeutics (NASDAQ:RLAY) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
12/15
10:36 am
rlay
Relay Therapeutics (RLAY): Revisiting Valuation After a Sharp Rebound in 2024 [Yahoo! Finance]
Medium
Report
Relay Therapeutics (RLAY): Revisiting Valuation After a Sharp Rebound in 2024 [Yahoo! Finance]
12/15
01:32 am
rlay
Will Broad Zovegalisib Breast Cancer Data Reshape Relay Therapeutics' (RLAY) Targeted Oncology Narrative? [Yahoo! Finance]
Medium
Report
Will Broad Zovegalisib Breast Cancer Data Reshape Relay Therapeutics' (RLAY) Targeted Oncology Narrative? [Yahoo! Finance]
12/12
07:39 am
rlay
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 [Yahoo! Finance]
Medium
Report
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 [Yahoo! Finance]
12/12
07:00 am
rlay
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
Low
Report
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
12/12
06:03 am
rlay
Relay Therapeutics (NASDAQ:RLAY) was upgraded by analysts at Wells Fargo & Company to an "overweight" rating.
Low
Report
Relay Therapeutics (NASDAQ:RLAY) was upgraded by analysts at Wells Fargo & Company to an "overweight" rating.